Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adi Mor George
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Beta
- 0.66
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -8.27
Financials
Net Income
$-1.77MEBITDA
$-1.83MFree Cash Flow
$0.00EPS (diluted)
$-0.22Shares Outstanding (diluted)
7.98M+195.1%Operating Expenses
$1.85MCash & Debt
$8.04MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-8.99M | $-1.42 |
| 2024 | $0.00 | $-13.95M | $-3.12 |
| 2023 | $0.00 | $-24.22M | $-8.22 |
| 2022 | $0.00 | $-27.65M | $-9.68 |
| 2021 | $0.00 | $-12.48M | $-4.80 |
| 2020 | $0.00 | $-5.95M | $-25.21 |
| 2019 | $0.00 | $-27.21M | $-63.20 |
| 2018 | $0.00 | $-13.80M | $-87.09 |
| 2017 | $0.00 | $-9.81M | $-875.98 |
| 2016 | $0.00 | $-4.73M | $-69.00 |
| 2015 | $0.00 | $-7.50M | $-131.76 |
| 2014 | $0.00 | $-6.00M | $-173.56 |
| 2013 | $0.00 | $-5.83M | $-318.95 |
| 2012 | $0.00 | $24.18M | $-833.25 |
Valuation
CMMBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Negative
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end
View source ↗
Earnings
Fri, Nov 6(in 3 months)
Consensus estimate $-0.01 per share
Typical surprise -180.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-0.27 vs $-0.04miss
- Thu, May 14$-0.22 vs $-0.04miss
- Thu, Mar 19$-0.24 vs $-0.20miss
- Thu, Nov 13$-0.02 vs $-0.20beat
- Thu, Aug 14$-0.36 vs $-0.20miss
- Thu, May 15$-0.56 vs $-0.20miss
Estimates and results for CMMB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CMMB officers and directors.
- Bought
- $31k
- Sold
- $2.5m
7 trades
7 trades
- Mor George Adibought
- Mor George Adibought
- Orbimed Israel Gp Ltd.sold
- Orbimed Israel Gp Ltd.sold
- Mor George Adisold
- Mor George Adisold
- Cohen Neil Harrissold
- Mor George Adisold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.